Le Meur Y, Potelune N, Jaccard A, Petit B, Bordessoule D, Peyronnet P, Ranger S, Labrousse F, Leroux-Robert C
Service de néphrologie, Centre hospitalier universitaire Dupuytren, Limoges.
Nephrologie. 1998;19(5):255-61.
Following kidney transplantation, lymphoproliferative disorders (LD) are encountered at a frequency of 1%. The onset of these LD is correlated with the degree of immunosuppression. The mortality is elevated (> 50%) especially in late forms. Since 1984 we have performed two hundred and seventeen kidney transplantations. The patients received sequential quadruple-drug immunosuppressive therapy: antilymphocyte globulin (ALG), azathioprine, corticosteroids and cyclosporine. A diagnosis of LD was established in ten patients, four were of early onset (within twelve months of transplantation) and six late (after five to nine years). Rejection occurred in two patients, one of which was steroid resistant requiring ALG. Three LD arose from the graft hilum, four had a voluminous tumor mass with extranodal sites: the graft (1), stomach (2), gingiva (1), meninges (1), and bone marrow (1). Histologically there were eight cases of large-cell B lymphoma, 1 mononucleosis-like LD, and a MALT lymphoma. A search for EBV was positive seven times. Treatment consisted of decreasing immunosuppressive therapy only (1), combined with antiviral treatment (1), or with surgical removal of the graft (3), and/or chemotherapy (5). Nine patients are still alive, in complete remission, graft loss occurred in four cases.
In our series, we found a high frequency of LD. Despite 4 LD with a voluminous tumor mass and unfavorable histological prognosis requiring chemotherapy, all the LD in our series had a favorable outcome.
肾移植后,淋巴增殖性疾病(LD)的发生率为1%。这些LD的发生与免疫抑制程度相关。死亡率升高(>50%),尤其是在晚期病例中。自1984年以来,我们共进行了217例肾移植手术。患者接受序贯四联免疫抑制治疗:抗淋巴细胞球蛋白(ALG)、硫唑嘌呤、皮质类固醇和环孢素。10例患者确诊为LD,4例为早期发病(移植后12个月内),6例为晚期发病(5至9年后)。2例患者发生排斥反应,其中1例对类固醇耐药,需要使用ALG。3例LD起源于移植肾门,4例有巨大肿瘤肿块并伴有结外部位:移植肾(1例)、胃(2例)、牙龈(1例)、脑膜(1例)和骨髓(1例)。组织学检查有8例大细胞B淋巴瘤、1例单核细胞增多症样LD和1例黏膜相关淋巴组织淋巴瘤。7次检测EBV呈阳性。治疗方法包括仅减少免疫抑制治疗(1例)、联合抗病毒治疗(1例)、或手术切除移植肾(3例)和/或化疗(5例)。9例患者仍存活,处于完全缓解状态,4例发生移植肾丢失。
在我们的系列研究中,我们发现LD的发生率较高。尽管有4例LD伴有巨大肿瘤肿块且组织学预后不良需要化疗,但我们系列中的所有LD均有良好的结局。